Edgewise Therapeutics jumps 11.9% on report of takeover interest
Seeking Alpha · · AI-summarised by FinFlash
Shares of Edgewise Therapeutics climbed 11.94% in late-morning New York trading after a report said the clinical-stage biotech has drawn takeover interest. The move came as the broader market attempted to recover from Thursday's tech-led sell-off, with the Nasdaq Composite up more than 1% at the time. No buyer or deal terms were confirmed in the report, and the company has not announced any transaction.
So What?
Biotech M&A speculation remains a support for small- and mid-cap drug developers; EWTX could retrace if no bid materialises.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.